Glioma Stem Cells: Signaling, Microenvironment, and Therapy - PubMed (original) (raw)

Review

Glioma Stem Cells: Signaling, Microenvironment, and Therapy

Brandon D Liebelt et al. Stem Cells Int. 2016.

Abstract

Glioblastoma remains the most common and devastating primary brain tumor despite maximal therapy with surgery, chemotherapy, and radiation. The glioma stem cell (GSC) subpopulation has been identified in glioblastoma and likely plays a key role in resistance of these tumors to conventional therapies as well as recurrent disease. GSCs are capable of self-renewal and differentiation; glioblastoma-derived GSCs are capable of de novo tumor formation when implanted in xenograft models. Further, GSCs possess unique surface markers, modulate characteristic signaling pathways to promote tumorigenesis, and play key roles in glioma vascular formation. These features, in addition to microenvironmental factors, present possible targets for specifically directing therapy against the GSC population within glioblastoma. In this review, the authors summarize the current knowledge of GSC biology and function and the role of GSCs in new vascular formation within glioblastoma and discuss potential therapeutic approaches to target GSCs.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Summary of key molecular pathways regulating steps in glioma stem cell self-renewal, differentiation, and gliomagenesis.

References

    1. Walker M. D., Green S. B., Byar D. P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. The New England Journal of Medicine. 1980;303(23):1323–1329. doi: 10.1056/nejm198012043032303. - DOI - PubMed
    1. DeAngelis L. M. Brain tumors. The New England Journal of Medicine. 2001;344(2):114–123. doi: 10.1056/nejm200101113440207. - DOI - PubMed
    1. Stupp R., Hegi M. E., Mason W. P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459–466. doi: 10.1016/s1470-2045(09)70025-7. - DOI - PubMed
    1. Stupp R., Mason W. P., Van Den Bent M. J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10):987–996. doi: 10.1056/nejmoa043330. - DOI - PubMed
    1. Grossman S. A., Batara J. F. Current management of glioblastoma multiforme. Seminars in Oncology. 2004;31(5):635–644. doi: 10.1053/j.seminoncol.2004.07.005. - DOI - PubMed

Publication types

LinkOut - more resources